Latest Intelligence on Pharmaceuticals and Healthcare in Netherlands

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Statins: can the third generation make an impression?

In November 2002 Crestor, AstraZeneca's third generation statin, received its first approval, marking the arrival of the new "superstatins" and illustrating the new threat to the current market leaders Pfizer and Merck & Co. However, this new generation of dyslipidemia treatments may not be as successful as earlier launched products and may suffer from the maturing nature of the market.

Published By Datamonitor
10 Jan 2003
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001
Expert View
Expert View

Pharmacy liberalization on hold: a sign of things to come?

While the EU's decision to halt the process of pharmacy liberalization is clearly based on the merit of one specific case (namely Doc Morris, the leading European online pharmacy), it could herald a sea change in terms of EU decision making. The move away from excessive deregulation towards a slower and more considered approach will bring both costs and benefits for EU consumers and patients.

Published By Datamonitor
19 Dec 2008
Expert View
Expert View

Pharmaceutical Licensing Weekly Review: August 19 - 23, 2002

Last week's licensing news featured three of the world's biggest pharmaceutical companies: first GlaxoSmithKline joined Pfizer in an alliance with Argonaut, then Pharmacia joined forces with BattellePharma. Johns Hopkins University also had a busy week beating out deals with Crucell and Correlogic Systems. Finally Amgen and Praecis agreed to terminate their failed relationship.

Published By Datamonitor
23 Aug 2002
CommentWire
CommentWire

Organon: Remeron best for stressed depressives

Published By Datamonitor
09 Aug 2001
CommentWire
CommentWire

Organon: lowest dose contraceptive pill on the market

Published By Datamonitor
15 Jun 2001
CommentWire
CommentWire

Organon/Pfizer: end of schizophrenic relationship

With an impending IPO, Organon has been dealt a blow with the withdrawal of Pfizer's marketing clout for the potential blockbuster schizophrenia treatment asenapine. In order to maximize the sales return on this late stage candidate, Organon needs to establish another collaboration with a strong US focus to crack the world's biggest market.

Published By Datamonitor
29 Nov 2006
CommentWire
CommentWire

Merck: generic Singulair threat becomes reality

As anticipated, Merck is about to face a significant decrease in revenue as the first generic versions of its blockbuster Singulair reach the US market. Although Merck's strong pipeline is aimed at offsetting the impact of generic erosion, little can be done in the immediate future to stem this loss.

Published By Datamonitor
06 Aug 2012
Expert View
Expert View

Licensing Week - August 16, 2002

Last week's licensing news had a truly global feel, with companies from the US, the UK, mainland Europe and Japan getting in on the action. The week saw deals between; AstraZeneca and Xenogen; Crucell and GenVec; Takeda and Human Genome Sciences; Adolor and Eli Lilly; and Anadys and Roche.

Published By Datamonitor
15 Aug 2002
CommentWire
CommentWire

EULAR: Roche and BMS target RA market

By presenting new data at the rheumatology conference currently being held in Amsterdam, Roche and Bristol-Myers Squibb are hoping to encourage uptake of their recently approved rheumatoid arthritis drugs. Although the data illustrates the addition of valuable new treatment options, an increasingly competitive market is set to limit the impact of Rituxan and Orencia in this indication.

Published By Datamonitor
23 Jun 2006

« | 1 | 2 | » »|

No help is available.